GILD

Gilead Sciences, Inc (NASDAQ: GILD) Sec Form 8K

Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, has reported a decline in adjusted earnings for the fourth quarter…

Gilead Sciences, Inc (NASDAQ: GILD) Q1 2026 Dividend Update

Gilead Sciences, Inc (NASDAQ: GILD) Q4 2025 Earnings Conference

Gilead Sciences, Inc (NASDAQ: GILD) FY 2026 Other Release

Gilead Sciences, Inc (NASDAQ: GILD) Q2 2025 Earnings Call dated Aug. 07, 2025 Corporate Participants: Jacquie Ross — Senior Vice…

Gilead Sciences, Inc (NASDAQ: GILD) Q3 2025 Earnings Call dated Oct. 30, 2025 Corporate Participants: Jacquie Ross — Senior Vice…

Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.6 billion for the second quarter of 2023, which was up…

Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.4 billion for the first quarter of 2023, which was down…

Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of…